Loading
Pamidronate (Aredia) is a bisphosphonate infusion approved in 1991 for dangerously high blood calcium in cancer and later for bone damage from myeloma and breast cancer, where it roughly halved skeletal complications. Its two-hour infusion, against fifteen minutes for zoledronic acid, pushed most centres to switch, though it is cheaper and may cause less jaw osteonecrosis.
Pamidronate disodium was approved in October 1991 for moderate or severe hypercalcaemia of malignancy with or without bone metastases and later for osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma in conjunction with standard antineoplastic therapy, on placebo-controlled trials (Hortobagyi 1996, Berenson 1996) that roughly halved skeletal complications. The two-hour infusion, compared with fifteen minutes for zoledronic acid, and the pivotal head-to-head hypercalcaemia trials led most centres to switch, although pamidronate remains a lower-cost generic option and is preferred by some in myeloma because of a lower rate of osteonecrosis of the jaw in observational series. Renal toxicity with rapid infusion, acute-phase reactions and jaw osteonecrosis are the key risks.
Adsorbs to hydroxyapatite and inhibits osteoclast-mediated bone resorption, lowering serum calcium and reducing osteolytic lesion progression.
1.Pamidronate slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| US | 1991 | Hypercalcaemia of malignancy |
| US | 1995 | Osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma, with antineoplastic therapy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pamidronate" OR ABSTRACT:"Pamidronate" OR TITLE:"Aredia" OR ABSTRACT:"Aredia" OR TITLE:"historic" OR ABSTRACT:"historic") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pamidronate, not a curated reading list.
Shares HR-positive / HER2-negative breast cancer and the tags generic, supportive.
Shares Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma, Multiple myeloma and the tags generic, supportive.
Shares the tags generic, supportive.
Shares the tags generic, supportive.
Shares the tags generic, supportive.
Shares the tags generic, supportive.
Shares Bone-modifying agents (bisphosphonates, denosumab), Denosumab, Zoledronic acid, HR-positive / HER2-negative breast cancer and the tag supportive.
Shares Bone-modifying agents (bisphosphonates, denosumab), Multiple myeloma, HR-positive / HER2-negative breast cancer and the tag supportive.